Reed's oncologist submitted a request through the FDA's Expanded Access Program, which can allow patients with serious or life-threatening illnesses to receive treatments outside of clinical trials when other options are limited. Daraxonrasib, also known as RMC-6236, is an investigational once-daily oral pill developed by Revolution Medicines. The drug targets mutated KRAS proteins, which drive more than 90 percent of pancreatic cancers. Reed spent 62 days waiting to learn whether he would be approved to receive the experimental drug after traditional treatments were no longer effective.
Just two days after sharing their story with WPTV, Reed learned he had been approved to receive the treatment. The drug is now in his hands, and his family says he is already feeling better and optimistic about what comes next.
Reed said research and clinical trial results gave him hope that daraxonrasib could help slow the progression of his disease. While daraxonrasib is not considered a cure for pancreatic cancer, the Reeds say the approval represents something they have been fighting for all along: more time together. Marnie Reed said the fight was never just about accessing a drug but about more family trips, more memories and more moments together.



